| Literature DB >> 24719452 |
Jennifer E Huffman1, Maja Pučić-Baković2, Lucija Klarić2, René Hennig3, Maurice H J Selman4, Frano Vučković2, Mislav Novokmet2, Jasminka Krištić2, Matthias Borowiak5, Thilo Muth3, Ozren Polašek6, Genadij Razdorov7, Olga Gornik7, Rosina Plomp4, Evropi Theodoratou8, Alan F Wright1, Igor Rudan8, Caroline Hayward1, Harry Campbell8, André M Deelder4, Udo Reichl9, Yurii S Aulchenko10, Erdmann Rapp3, Manfred Wuhrer11, Gordan Lauc12.
Abstract
The biological and clinical relevance of glycosylation is becoming increasingly recognized, leading to a growing interest in large-scale clinical and population-based studies. In the past few years, several methods for high-throughput analysis ofEntities:
Mesh:
Substances:
Year: 2014 PMID: 24719452 PMCID: PMC4047478 DOI: 10.1074/mcp.M113.037465
Source DB: PubMed Journal: Mol Cell Proteomics ISSN: 1535-9476 Impact factor: 5.911
Fig. 1.Representative data from IgG glycosylation analysis of the same individual by (A) UPLC-FLR (continuous lines - total IgG N-glycans), (B) MALDI-TOF-MS (dotted lines - tryptic IgG1 Fc N-glycopeptide [M-H]− ions, striated lines - IgG2&3 Fc N-glycopeptide [M-H]− ions), (C) xCGE-LIF (continuous lines - total IgG N-glycans), and (D) LC-ESI-MS (dotted lines - tryptic IgG1 Fc N-glycopeptide [M+2H]2+ and [M+3H]3+ ions). Structural schemes are given in terms of pep (peptide moiety), blue square (N-acetylglucosamine), red triangle (fucose), green circle (mannose), yellow circle (galactose), and purple diamond (N-acetylneuraminic acid). Linkage information is given to indicate separation of linkage isomers by UPLC-FLR and xCGE-LIF. Glycan structures are assigned to most of the signals. The complete list of the assigned IgG N-glycans (UPLC-FLR and xCGE-LIF) and IgG N-glycopeptides (MALDI-TOF-MS and LC-ESI-MS) with the charge states corresponding m/z values is given in supplementary Table S1.
Minimal shared dataset and median values for these IgG glycan structures and traits measured by four different methods
p values for significant associations between genetic polymorphisms and glycan structures or traits obtained by different methods. Bold text indicates that the p value reaches genome wide significance (p < 5 × 10−8)
| Glycan Structure Or Trait | Genes in Associated Region | SNP | Association p-Value | |||||
|---|---|---|---|---|---|---|---|---|
| UPLC-FLR | MALDI-TOF-MS (IgG1) | MALDI-TOF-MS (IgG2&3) | LC-ESI-MS (IgG1) | LC-ESI-MS (IgG2&3) | xCGE-LIF | |||
| FA2BG1 | SMARCB1; DERL3 | rs9620326 | 1.15E-07 | 1.70E-06 | ||||
| 1.54E-04 | 7.46E-06 | |||||||
| FA2G1S1 | ST6GAL1 | rs6764279 | 0.2556 | |||||
| FGS/(FG+FGS) | ST6GAL1 | rs6764279 | 0.0154 | |||||
| FGS/(F+FG+FGS) | ST6GAL1 | rs6764279 | 3.25E-04 | 0.1008 | 1.97E-04 | 1.21E-05 | 3.82E-07 | |
| FG1S1/(FG1+FG1S1) | ST6GAL1 | rs6764279 | 0.3941 | |||||
| FG2S1/(FG2+FG2S1+FG2S2) | ST6GAL1 | rs6764279 | ||||||
This glycan structure is measured as two isomers with UPLC-FLR and xCGE-LIF (FA2[6]BG1, with galactose on the 6-arm and FA2[3]BG1, with galactose on the 3-arm), but as only one mass in the MS methods.
Correlation of age and glycan structures or traits measured by different methods in Vis cohort. Presented p values are corrected for multiple testing using Bonferroni correction. Significance level is set at p ≤ 5.3 × 10−4 (94 tests)
| Glycan Class | Glycan Structure or Trait | UPLC-FLR (Total IgG) | MALDI-TOF-MS | LC-ESI-MS | xCGE-LIF (Total IgG) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG1 | IgG2&3 | IgG1 | IgG2&3 | ||||||||||
| R | p | R | p | R | p | R | p | R | p | R | p | ||
| FA2 | 0.598 | 1.28E-46 | 0.560 | 1.95E-39 | 0.626 | 2.01E-52 | 0.554 | 1.74E-38 | 0.621 | 2.57E-51 | 0.575 | 3.25E-42 | |
| FA2B | 0.562 | 6.91E-40 | 0.472 | 2.70E-26 | 0.451 | 1.26E-23 | 0.557 | 5.65E-39 | 0.536 | 1.49E-35 | 0.555 | 1.15E-38 | |
| FA2G1 | −0.347 | 4.57E-13 | −0.499 | 5.44E-30 | −0.585 | 4.47E-44 | −0.117 | 1.00E+00 | −0.405 | 1.56E-18 | −0.255 | 1.83E-06 | |
| −0.107 | 1.00E+00 | −0.035 | 1.00E+00 | ||||||||||
| FA2BG1 | 0.026 | 1.00E+00 | −0.085 | 1.00E+00 | −0.396 | 1.49E-17 | 0.053 | 1.00E+00 | −0.226 | 8.25E-05 | 0.047 | 1.00E+00 | |
| 0.296 | 4.63E-09 | 0.330 | 1.32E-11 | ||||||||||
| FA2G2 | −0.646 | 5.71E-57 | −0.609 | 1.06E-48 | −0.638 | 4.02E-55 | −0.617 | 2.15E-50 | −0.634 | 2.92E-54 | −0.626 | 1.77E-52 | |
| FA2BG2 | −0.393 | 2.89E-17 | −0.333 | 6.46E-12 | −0.507 | 4.34E-31 | −0.422 | 2.34E-20 | −0.520 | 5.09E-33 | −0.361 | 3.22E-14 | |
| FA2G1S1 | 0.062 | 1.00E+00 | −0.026 | 1.00E+00 | −0.494 | 2.92E-29 | 0.176 | 1.61E-02 | −0.331 | 1.01E-11 | 0.003 | 1.00E+00 | |
| FA2G2S1 | −0.588 | 1.35E-44 | −0.519 | 6.58E-33 | −0.589 | 6.72E-45 | −0.585 | 5.75E-44 | −0.619 | 7.82E-51 | −0.584 | 8.00E-44 | |
| FGS/(FG+FGS) | −0.259 | 1.08E-06 | −0.081 | 1.00E+00 | −0.446 | 5.31E-23 | −0.436 | 7.63E-22 | −0.372 | 2.79E-15 | −0.457 | 2.17E-24 | |
| FGS/(F+FG+FGS) | −0.593 | 1.30E-45 | −0.336 | 4.04E-12 | −0.577 | 1.55E-42 | −0.543 | 1.25E-36 | −0.586 | 2.99E-44 | −0.557 | 6.38E-39 | |
| FG1S1/(FG1+FG1S1) | 0.194 | 2.84E-03 | 0.113 | 1.00E+00 | −0.072 | 1.00E+00 | 0.252 | 2.85E-06 | −0.074 | 1.00E+00 | 0.015 | 1.00E+00 | |
| FG2S1/(FG2+FG2S1+FG2S2) | 0.203 | 1.06E-03 | 0.070 | 1.00E+00 | −0.186 | 6.41E-03 | −0.063 | 1.00E+00 | −0.120 | 1.00E+00 | 0.087 | 1.00E+00 | |
| G0n | 0.626 | 1.68E-52 | 0.585 | 4.42E-44 | 0.639 | 3.36E-55 | 0.586 | 2.70E-44 | 0.638 | 4.71E-55 | 0.598 | 1.38E-46 | |
| G1n | −0.473 | 2.05E-26 | −0.495 | 2.13E-29 | −0.605 | 5.94E-48 | −0.373 | 2.33E-15 | −0.580 | 4.40E-43 | −0.406 | 1.31E-18 | |
| G2n | −0.638 | 5.51E-55 | −0.605 | 6.26E-48 | −0.637 | 8.22E-55 | −0.618 | 1.15E-50 | −0.648 | 2.48E-57 | −0.622 | 1.24E-51 | |
These glycan structures are measured as two isomers with UPLC-FLR and xCGE-LIF (with galactose on 6- and 3-arm), but as single masses in the MS methods.
Comparison of four methods for high-throughput glycomic and glycoproteomic analysis
| UPLC-FLR | xCGE-LIF | MALDI-TOF-MS | LC-ESI-MS | |
|---|---|---|---|---|
| Widely used | Rarely used | Widely used | Moderately used | |
| Medium, approximately 50 samples per instrument per day | (Very) high, multiplexing with up to 96 capillaries enables analysis of thousands of samples | (Very) high, as measurement of a sample can be performed at a sub-minute time scale | Medium, approximately 100 samples per day per instrument | |
| Medium | Medium | High | Very high | |
| High | High | Very high | Very high | |
| Good | Very good | None | Some | |
| Very good | Good | Medium | Good | |
| Ca. Euro 40–70,000 | Ca. Euro 100,000 for a 4-capillary instrument | Ca. Euro 100–500,000 | Euro 200–500,000 | |
| Rather high costs, mainly due to low throughput and costs of consumables | Low costs per sample, due to low running costs and parallelization by multiplexing | Low costs per sample due to high throughput per instrument | Very high costs, mainly due to expensive equipment and low throughput per instrument | |
| Reliable quantification, robustness | Less demanding in sample preparation, low costs, high robustness and high throughput, no sample carry over; reliable relative quantification, very sensitive (low LOD) | Low cost and high throughput, site specific glycosylation analysis, sensitive, enables structural elucidation via fragmentation experiments | Reliable quantification, site specific glycosylation analysis, sensitive, enables structural elucidation via fragmentation experiments | |
| Inability to perform site specific glycosylation analysis, relatively low throughput and high cost | Inability to perform site specific glycosylation analysis, comparatively small database (to be enlarged) | Less reliable quantification, loss of sialic acids | Relatively high costs | |
| Differentiation of galactosylation on 3- and 6-arms, accurate quantification of IgG sialylation | Differentiation of galactosylation on 3- and 6-arms, accurate quantification of IgG sialylation | Differentiation of glycans on different IgG subclasses, analysis of only Fc glycans | Differentiation of glycans on different IgG subclasses, analysis of only Fc glycans, accurate quantification of IgG sialylation |